Literature DB >> 1989664

Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites.

F Y Lee1.   

Abstract

Evidence was obtained showing that GSH protects against the cytotoxicity of 4-hydroperoxycyclophosphamide (4-OOH-CP) by minimizing the spontaneous fission of 4-hydroxycyclophosphamide (4-OH-CP), its breakdown product, to the ultimate toxic species, phosphoramide mustard (PM). This conclusion was borne out in two series of experiments. The first demonstrated that 4-OH-CP was progressively more stable in aqueous solutions containing increasing concentrations of GSH. The second series of experiments were carried out with tumour cell lines with high (SKOV-3) and low (KHT) GSH contents. The cytotoxicity of 4-OOH-CP, a stable precursor that rapidly gives rise to 4-OH-CP spontaneously under physiological conditions, was enhanced in GSH-depleted SKOV-3 cells, but was unchanged in GSH-depleted KHT cells. It is concluded that the high GSH content of SKOV-3 cells provides a significant protection against 4-OH-CP by limiting the breakdown/activation of 4-OH-CP. Deschloro-4-hydroperoxycyclophosphamide (deschloro-4-OOH-CP), an analogue of 4-OOH-CP that generates acrolein (AC) but not PM in the spontaneous fission reaction, is essentially non-toxic when compared with 4-OOH-CP but is equally potent in depleting GSH. It is postulated that AC may promote the cytotoxicity of the parent 4-OH-CP by depleting cellular GSH. Consequently, the stabilising influence of GSH on 4-OH-CP is removed, leading to increased formation of PM, the ultimate cytotoxic agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989664      PMCID: PMC1971657          DOI: 10.1038/bjc.1991.10

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Effect of thiol manipulation on chemopotentiation by nitroimidazoles.

Authors:  D W Siemann; A A Flaherty; D P Penney
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

2.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

Review 3.  Redox properties and rate constants in free-radical mediated damage.

Authors:  P Wardman; E D Clarke
Journal:  Br J Cancer Suppl       Date:  1987-06

4.  Glutathione as a determinant of cellular response to doxorubicin.

Authors:  F Y Lee; A R Vessey; D W Siemann
Journal:  NCI Monogr       Date:  1988

5.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

Review 6.  The roles of intracellular glutathione in antineoplastic chemotherapy.

Authors:  A Russo; J Carmichael; N Friedman; W DeGraff; Z Tochner; E Glatstein; J B Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

7.  Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.

Authors:  K Ono; D C Shrieve
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

8.  Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism.

Authors:  C H Kwon; R F Borch; J Engel; U Niemeyer
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

9.  Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide.

Authors:  T R Crook; R L Souhami; G D Whyman; A E McLean
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Heterogeneity of glutathione content in human ovarian cancer.

Authors:  F Y Lee; A Vessey; E Rofstad; D W Siemann; R M Sutherland
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

View more
  6 in total

1.  Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).

Authors:  Jing Zhang; Ka-Yun Ng; Paul C Ho
Journal:  AAPS J       Date:  2010-04-20       Impact factor: 4.009

2.  Acacia Senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity.

Authors:  Abdulaziz A Al-Yahya; Abdulhakeem A Al-Majed; Ali M Gado; Mohammad H Daba; Othman A Al-Shabanah; Adel R A Abd-Allah
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

3.  Development of a model of melphalan-induced gastrointestinal toxicity in mice.

Authors:  S Castellino; G B Elion; O W Griffith; M Dewhirst; J Kurtzberg; R C Cattley; P Scott; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients.

Authors:  R Smaaland; J F Abrahamsen; A M Svardal; K Lote; P M Ueland
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

6.  Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation.

Authors:  S M Lee; D Crowther; J H Scarffe; M Dougal; R H Elder; J A Rafferty; G P Margison
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.